Atilla ERSEN, Ferhan KARADEMİR, Mustafa ÖZYURT, Selami SÜLEYMANOĞLU, Seçil AYDINÖZ, Cihan MERAL, Gökhan AYDEMİR, İsmail GÖÇMEN

Seroprevalence of Immunoglobulin M/A/G antibodies against Bordetella pertussis and Bordetella parapertussis among asymptomatic children at 6-8 of age in Turkey

Abstract. Bordetella pertussis infection is a vaccine preventable disease, but immunity following the vaccination is not life-long. Moreover parapertussis may share similar clinical presentation with pertussis and mostly recognized in prolonged bronchitis. Although the serology of pertussis has been well studied, those of parapertussis have not. We herein investigated antipertussis and antiparapertussis serology in asymptomatic healthy children. We examined IgM, IgA and IgG antibodies against B. pertussis and B. parapertussis among 100 asymptomatic children aged from 6 to 8 years who got regular vaccination. The antibody titers were measured by indirect immunofluorescence test (IFA). 10% of them had IgA titers of > or = 100 EU/ml, 33% had IgM titers of > or = 320 EU/ml who could be considered as acute or recent pertussis infection and 89% had IgG titers > or = 100 EU/ml as a protective level of pertussis. Bordetella parapertussis antibody levels of IgG, IgA and IgM were detected in 33%, 17%, and 11% respectively. We suggest 2 explanations for the acquisition of pertussis and parapertussis antibodies in our children: (1) asymptomatic pertussis and parapertussis infections are common; (2) Although higher values of IgG observed, acute infection markers still persisted, and one problem in this regard may be waning immunity against pertussis. Of the strategies considered, the addition of a preschool booster is therefore a priority in Turkey.Key words: Asymptomatic children, Bordetella parapertussis, Bordetella pertussis, seroprevalence

Keywords:

Asymptomatic children, Bordetella parapertussis, Bordetella pertussis, seroprevalence,

PDF

___

1. Taranger J, Trollfors B, Bergfors E, et al. Mass vaccination of children with pertussis toxoiddecreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis 2001; 33: 1004-1010.
2. Cherry JD, Olin P. The science and fiction of pertussis vaccines. Pediatrics 1999; 104: 1381-1383.
3. Trollfors B, Taranger J, Lagergârd T, et al. Immunization of children with pertussis toxoid decreases spread of pertussis within the family. Pediatr Infect Dis J 1998; 17: 196-199.
4. Romanus V, Jonsell R, Bergquist SO. Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr Infect Dis J 1987; 6: 364-371.
5. Vatansever U, Cöplü N, Oner N, et al. Seroprevalance of Bordetella pertussis antibodies among healthy adolescent girls in Edirne. Swiss Med Wkly 2005; 135: 531-536.
6. General Directorate of Primary Health Care of Ministry of Health, Turkey. The Annual of Statistics 2001.Table38,40.www.saglik.gov.tr/extras/istatistikl er/temel2001/103.html.
7. Yildirim I, Ceyhan M, Kalayci O, et al. Frequency of pertussis in children with prolongued cough. Scand J Infect Dis 2008; 40: 314-319.
8. Forsyth KD, Campins-Marti M, Caro J, et al. New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis 2004; 39: 1802-1809.
9. Cherry JD. The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 2005; 115: 1422-1427.
10. Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence from a 10-year community study. Br Med J 1988; 296: 612-614.
11. Mertsola J. Mixed outbreak of Bordetella pertussis and Bordetella parapertussis infection in Finland. Eur J Clin Microbiol 1985; 4: 123-128.
12. He Q, Viljanen MK, Arvilommi H, Aittanen B, Mertsola J. Whooping cough caused by Bordatela pertussis and Bordatella parapertussis in immunized population. JAMA 1998; 280: 635-637.
13. www.euroimmun.com.
14. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev 2005; 18: 326-382.
15. Munoz FM. Pertussis in infants, children, and adolescents: diagnosis, treatment, and prevention. Semin Pediatr Infect Dis 2006; 17: 14-19.
16. Gustafsson L, Hessel L, Storsaeter J, Olin P. Longterm follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 2006; 118: 978-984.
17. Heininger U. Update on pertussis in children. Expert Rev Anti Infect Ther 2010; 8: 163-173.
18. Salmaso S, Mastrantonio P, Tozzi AE, et al. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 2001; 108: 8
19. Kourova N, Caro V, Weber C, et al. Comparison of the Bordetella pertussis and Bordetella parapertussis isolates circulating in Saint Petersburg between 1998 and 2000 with Russian vaccine strains. J Clin Microbiol 2003; 41: 3706-3711.
20. Tozzi AE, Rava L, Ciofi degli Atti ML, et al. Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six years of life. Pediatrics 2003; 112: 1069-1075.
21. Vickers D, Ross AG, Mainar-Jaime RC, Neudorf C, Shah S. Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children. CMAJ 2006; 175: 1213- 1217.
22. Cöplü N, Nar S, Efsun A, Kurtoğlu D, Esen B. A field survey carried out on the confirmation of a pertussis case in a village of Kirikkale Province, Turkey. Mikrobiyol Bul 2007; 41: 175-183.
23. Kurtoğlu D, Gözalan A, Cöplü N, et al. Pertussis seroprevalence and vaccination status in three selected provinces of Turkey. Mikrobiyol Bul 2008; 42: 389-398.
24. Esen B, Coplu N, Kurtoglu D, Gozalan A, Akin L. Prevalence of high antibody titers of pertussis in Turkey: reflection of circulating microorganism and a threat to infants. J Clin Lab Anal 2007; 21: 154- 161.
25. Watanabe M, Nagai M. Whooping cough due to Bordetella parapertussis: an unresolved problem. Expert Rev Anti Infect Ther 2004; 2: 447-454.